Veterinary Active Pharmaceutical Ingredients Manufacturing Global Market Report 2026
상품코드:1938705
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
수의용 원료의약품 제조 시장 규모는 최근 현저한 성장을 달성하고 있습니다. 2025년 80억 3,000만 달러에서 2026년에는 87억 1,000만 달러로, CAGR 8.5%로 확대할 전망입니다. 지난 수년간의 성장은 동물 질병 발생률 증가, 가축 및 반려동물 사육두수 증가, 수의학 산업의 확대, 기존 화학의약품의 개발, 항감염 및 항기생충제 수요 증가에 기인하는 것으로 보입니다.
수의용 원료의약품 제조 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2030년에는 120억 6,000만 달러에 달하며, CAGR은 8.5%에 달할 전망입니다. 예측 기간 중의 성장 요인으로는 생물제제 및 재조합 제제의 채택, 수탁제조 서비스 확대, 고효능 제제에 대한 수요 증가, 동물용 의약품 생산에 대한 규제 지원, 백신 제제 혁신에 대한 집중 강화 등을 들 수 있습니다. 예측 기간의 주요 동향으로는 수의약품 수탁제조의 성장, 고효능 제제 개발, 자체 제제 생산능력 확대, 항감염 및 항기생충 제제 집중 강화, 백신 제제 혁신 등이 있습니다.
인수공통전염병 증가 추세는 향후 수년간 동물용 원료의약품(API) 제조 시장의 성장을 가속할 것으로 예측됩니다. 인수공통전염병(Zoonoses)은 동물과 사람 사이에 자연적으로 전파될 수 있는 감염병을 말합니다. 사람과 동물의 접촉 기회가 증가함에 따라 병원체가 확산되어 새로운 감염을 일으킬 수 있는 기회가 증가함에 따라 인수공통전염병의 발생률은 증가 추세에 있습니다. 수의용 API는 동물에서 사람으로의 인수공통전염병 전파를 막는 백신 개발에 사용됩니다. 또한 수의용 API의 사용은 인수공통전염병 치료의 심각한 문제인 항생제 내성 대책에도 기여할 수 있습니다. 예를 들어 미국에 본사를 둔 독립적이고 비당파적인 싱크탱크이자 출판사인 외교문제협의회(CFR)에 따르면 2023년 2월 현재 새로 발견되는 전염병 또는 신흥 전염병(EID)의 최대 75%, 알려진 전염병의 60%가 인수공통전염병에 기인한다고 합니다. 전 세계에서 인수공통전염병은 매년 270만 명의 사망과 25억 건의 질병을 유발하고 있습니다. 따라서 인수공통전염병 증가 추세가 수의용 원료의약품 제조 시장의 성장을 촉진하고 있습니다.
동물용 원료의약품 제조 시장의 주요 기업은 경쟁 우위를 확보하기 위해 제조시설 설립에 집중하고 있습니다. 이들 공장에서는 동물용 의약품의 제제에 사용되는 의약품 유효성분을 생산하고 있습니다. 예를 들어 2023년 10월 인도에 본사를 둔 동물용의약품 기업 스탈렌 사우스 아시아 프라이빗 리미티드(Stallen South Asia Private Limited)는 하이드록시 퀴놀린 계열의 비항생제 성장 촉진제인 할퀴놀(Halquinol)의 새로운 동물용 원료의약품 생산 시설을 개설했습니다. 이 시설에서는 5-클로로-8-하이드록시퀴놀린, 5,7-디클로로-8-하이드록시퀴놀린, 7-클로로-8-하이드록시퀴놀린의 조합을 생산하고 있습니다. 이 제품에는 영국 약전 1980년판(BP 80) 기준에 따라 제조된 할퀴놀 98%가 함유되어 있습니다. 일반적인 60% 및 12% 제제 외에도, 스탈렌은 동물용 의약품 및 사료첨가제용 화학 API로 98% 제제를 공급할 수 있습니다. 이 회사는 본 공장에서 다양한 API를 단계적으로 도입하여 동물용의약품 산업을 지원함으로써 중국으로부터의 수입 의존도를 낮추는 것을 목표로 하고 있습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 용도 산업의 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의에 의한 공급망에 대한 영향, Covid가 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 시장의 세계 TAM(Total Addressable Market)
제9장 시장 세분화
제10장 지역별·국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 대기업과 혁신적 기업
제38장 세계의 시장 경쟁 벤치마킹과 대시보드
제39장 주요 합병과 인수
제40장 시장의 잠재력이 높은 국가, 부문, 전략
제41장 부록
KSA
영문 목차
영문목차
Veterinary Active Pharmaceutical Ingredients (APIs) manufacturing involves the production of chemical compounds that are biologically active and utilized in the formulation of veterinary medicines. These APIs play a crucial role in treating diseases and maintaining health in animals, including both livestock and pets. The manufacturing process is designed to ensure the quality, safety, and efficacy of the medications that enhance animal welfare and health outcomes.
The primary products within veterinary active pharmaceutical ingredients manufacturing encompass anti-infectives, vaccines, and NSAIDs. Active Pharmaceutical Ingredients (APIs) are the core elements of pharmaceutical medications that exert specific effects on the body, aiding in the treatment of diseases. Service types associated with this field include in-house production and contract outsourcing. Additionally, synthetic types of APIs comprise chemical-based APIs, biological APIs, and highly potent APIs. These categories delineate the diverse methodologies involved in producing these vital components for veterinary pharmaceuticals.
Tariffs have influenced the veterinary active pharmaceutical ingredients manufacturing market by increasing the cost of imported raw materials, chemical intermediates, and biological components, disrupting supply chains for chemical, biological, and highly potent APIs. Regions such as North America and Europe, which rely heavily on imports for advanced API production, are most affected, particularly in anti-infective and vaccine API segments. On the positive side, tariffs promote local API manufacturing, encourage investment in domestic production facilities, and support development of cost-efficient veterinary medicines.
The veterinary active pharmaceutical ingredients manufacturing market research report is one of a series of new reports from The Business Research Company that provides veterinary active pharmaceutical ingredients manufacturing market statistics, including veterinary active pharmaceutical ingredients manufacturing industry global market size, regional shares, competitors with a veterinary active pharmaceutical ingredients manufacturing market share, detailed veterinary active pharmaceutical ingredients manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary active pharmaceutical ingredients manufacturing industry. This veterinary active pharmaceutical ingredients manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The veterinary active pharmaceutical ingredients manufacturing market size has grown strongly in recent years. It will grow from $8.03 billion in 2025 to $8.71 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to rising prevalence of animal diseases, growth of livestock and companion animal population, expansion of veterinary pharmaceutical industry, development of conventional chemical-based apis, increasing demand for anti-infective and antiparasitic drugs.
The veterinary active pharmaceutical ingredients manufacturing market size is expected to see strong growth in the next few years. It will grow to $12.06 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to adoption of biological and recombinant apis, growth in contract manufacturing services, rising demand for highly potent apis, regulatory support for veterinary pharmaceutical production, increasing focus on vaccine api innovations. Major trends in the forecast period include growth of contract manufacturing for veterinary apis, development of highly potent apis, expansion of in-house api production capabilities, increasing focus on anti-infective and antiparasitic apis, innovation in vaccine api formulations.
The rising prevalence of zoonotic diseases is expected to drive growth in the veterinary active pharmaceutical ingredients (API) manufacturing market in the coming years. Zoonotic diseases, also known as zoonoses, are infectious illnesses that can be transmitted naturally between animals and humans. The incidence of zoonotic diseases is increasing due to greater human-animal interactions, which provide more opportunities for pathogens to spread and establish new infections. Veterinary APIs are used in the development of vaccines that prevent the transmission of zoonotic diseases from animals to humans. Additionally, the use of veterinary APIs helps combat antibiotic resistance, a significant concern in treating zoonotic infections. For example, in February 2023, according to the Council on Foreign Relations (CFR), a US-based independent, nonpartisan think tank and publisher, up to 75% of newly discovered or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases had zoonotic origins. Globally, zoonoses cause 2.7 million human deaths and 2.5 billion disease episodes in people each year. Therefore, the increasing prevalence of zoonotic diseases is driving the veterinary API manufacturing market.
Leading players in the veterinary API manufacturing market are focusing on establishing manufacturing facilities to gain a competitive edge. These plants produce active pharmaceutical ingredients used in the formulation of veterinary drugs. For instance, in October 2023, Stallen South Asia Private Limited, an India-based animal health company, inaugurated a new veterinary API facility for Halquinol, a non-antibiotic growth promoter belonging to the hydroxyquinoline group. The facility produces a combination of 5-chloro-8-hydroxyquinoline, 5,7-dichloro-8-hydroxyquinoline, and 7-chloro-8-hydroxyquinoline. Products include Halquinol 98%, manufactured according to British Pharmacopeia 1980 (BP 80) standards. In addition to the more common 60% and 12% formulations, Stallen is able to supply 98% as a chemical API for veterinary formulations and feed additives. The company aims to reduce reliance on imports from China by gradually introducing a broad range of APIs from this plant to support the animal health industry.
In May 2024, Veterinary Pharmacy Corporation, a US-based provider of veterinary pharmacy products and animal health services, acquired Diamond Animal Health Inc. for an undisclosed amount. Through this acquisition, Veterinary Pharmacy Corporation expanded its contract manufacturing and pharmaceutical development capabilities in the animal health sector, enhancing its manufacturing footprint and broadening its portfolio of active pharmaceutical ingredients and biologics for veterinary applications. Diamond Animal Health Inc. is a US-based provider of contract manufacturing, research and development, and regulatory services for animal pharmaceuticals and vaccines, supporting API production and formulation for both livestock and companion animals.
Major companies operating in the veterinary active pharmaceutical ingredients manufacturing market are Alivira Animal Health Limited, Excel Industries Limited, Ofichem Group B.V., Jiangsu Lingyun Pharmaceutical Co. Ltd., SUANFARMA S.A., NGL Fine-Chem Limited, FIS - Fabbrica Italiana Sintetici S.p.A., Lupin Limited, Aurobindo Pharma Limited, Saneca Pharmaceuticals AS, Neuland Laboratories Limited, Divi's Laboratories Limited, Zoetis Inc., Grupo Indukern S.L., Sequent Scientific Limited, Chempro Pharma Private Limited, AMGIS Lifescience Ltd., Huvepharma AD, Vetpharma Animal Health S.L., Qilu Pharma Spain S.A., INDUKERN Chemie AG, Chemopharma S.A., Norbrook Laboratories Limited, Ceva Sante Animale S.A., Vetoquinol S.A., Virbac S.A.
North America was the largest region in the veterinary active pharmaceutical ingredients manufacturing market in 2025. The regions covered in the veterinary active pharmaceutical ingredients manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the veterinary active pharmaceutical ingredients manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The veterinary active pharmaceutical ingredients manufacturing market consists of revenues earned by entities by biologics and bulk drugs that are used to create components in medications which are responsible for the positive veterinary health impacts. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Veterinary Active Pharmaceutical Ingredients Manufacturing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses veterinary active pharmaceutical ingredients manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for veterinary active pharmaceutical ingredients manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The veterinary active pharmaceutical ingredients manufacturing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Product: Antiparasitic; Anti-Infectives; Vaccines; NSAIDs
2) By Service Type: In House; Contract Outsourcing
3) By Synthesis Type: Chemical Based API; Biological API; Highly Potent API
Subsegments:
1) By Antiparasitic: Endectocides; Anthelmintics; Antiprotozoals
2) By Anti-Infectives: Antibiotics; Antifungals; Antivirals
3) By Vaccines: Inactivated Vaccines; Live Attenuated Vaccines; Recombinant Vaccines
4) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Non-Selective NSAIDs; COX-2 Inhibitors
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
4.1.4 Industry 4.0 & Intelligent Manufacturing
4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Growth Of Contract Manufacturing For Veterinary Apis
4.2.2 Development Of Highly Potent Apis
4.2.3 Expansion Of In-House Api Production Capabilities
4.2.4 Increasing Focus On Anti-Infective And Antiparasitic Apis
4.2.5 Innovation In Vaccine Api Formulations
5. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Analysis Of End Use Industries
5.1 Veterinary Pharmaceutical Companies
5.2 Livestock Farms
5.3 Companion Animal Clinics
5.4 Contract Manufacturing Organizations
5.5 Research Laboratories
6. Veterinary Active Pharmaceutical Ingredients Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Veterinary Active Pharmaceutical Ingredients Manufacturing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size, Comparisons And Growth Rate Analysis
7.3. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Segmentation
9.1. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Antiparasitic, Anti-Infectives, Vaccines, NSAIDs
9.2. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
In House, Contract Outsourcing
9.3. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Chemical Based API, Biological API, Highly Potent API
9.4. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Sub-Segmentation Of Antiparasitic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Endectocides, Anthelmintics, Antiprotozoals
9.5. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Sub-Segmentation Of Anti-Infectives, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Antibiotics, Antifungals, Antivirals
9.6. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines
9.7. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Sub-Segmentation Of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Non-Selective NSAIDs, COX-2 Inhibitors
10. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Regional And Country Analysis
10.1. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Market
11.1. Asia-Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Veterinary Active Pharmaceutical Ingredients Manufacturing Market
12.1. China Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Veterinary Active Pharmaceutical Ingredients Manufacturing Market
13.1. India Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Market
14.1. Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Veterinary Active Pharmaceutical Ingredients Manufacturing Market
15.1. Australia Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Veterinary Active Pharmaceutical Ingredients Manufacturing Market
16.1. Indonesia Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Market
17.1. South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Veterinary Active Pharmaceutical Ingredients Manufacturing Market
18.1. Taiwan Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Veterinary Active Pharmaceutical Ingredients Manufacturing Market
19.1. South East Asia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market
20.1. Western Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Veterinary Active Pharmaceutical Ingredients Manufacturing Market
21.1. UK Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Market
22.1. Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Veterinary Active Pharmaceutical Ingredients Manufacturing Market
23.1. France Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Market
24.1. Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Market
25.1. Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market
26.1. Eastern Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Veterinary Active Pharmaceutical Ingredients Manufacturing Market
27.1. Russia Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Veterinary Active Pharmaceutical Ingredients Manufacturing Market
28.1. North America Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Veterinary Active Pharmaceutical Ingredients Manufacturing Market
29.1. USA Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Market
30.1. Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Veterinary Active Pharmaceutical Ingredients Manufacturing Market
31.1. South America Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Market
32.1. Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Veterinary Active Pharmaceutical Ingredients Manufacturing Market
33.1. Middle East Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market
34.1. Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Synthesis Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Regulatory and Investment Landscape
36. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Competitive Landscape And Company Profiles
36.1. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Veterinary Active Pharmaceutical Ingredients Manufacturing Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Company Profiles
36.3.1. Alivira Animal Health Limited Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Excel Industries Limited Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Ofichem Group B.V. Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Jiangsu Lingyun Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
36.3.5. SUANFARMA S.A. Overview, Products and Services, Strategy and Financial Analysis
37. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Other Major And Innovative Companies
